Industry ties may expand indications

Share this article:

A study of government drug review advisory panels suggests that those with members who have financial ties to the drug industry recommended expansion of labeled disease indications for the drugs examined.

Published in the online journal PLOS Medicine, the study by six Australian physicians sought to identify guidelines in which disease definitions were changed, and the extent of panel members' industry ties.

They looked at publications between 2000 and 2013 from guideline panels making decisions about definitions or diagnostic criteria for common conditions in the US. Of 16 publications on 14 conditions, 10 proposed changes widening and one narrowing definitions. Among panels with disclosure, the average proportion of members with ties was 75%.

The authors found that diagnostic thresholds are being lowered by panels dominated by those with financial ties to multiple companies that may benefit from those decisions, raising questions about current processes of disease definition.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Agency Gallery

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters